Biomarin Pharmaceutical reported $802.32M in Stock for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Stock Change
Acadia Pharmaceuticals ACAD:US $ 6.33M 0.68M
Alnylam Pharmaceuticals ALNY:US $ 88.98M 10.46M
Amgen AMGN:US $ 4554M 143M
Bayer BAYN:GR € 11371M 502M
Biogen BIIB:US $ 1294.2M 78.8M
Biomarin Pharmaceutical BMRN:US $ 802.32M 15.96M
Gilead Sciences GILD:US $ 2587M 88M
IONIS PHARMACEUT IONS:US $ 19.81M 4.22M
Moderna Inc MRNA:US 1.92B 21M
Neurocrine Biosciences NBIX:US $ 29.3M 0.3M
Ptc Therapeutics PTCT:US $ 15M 0.28M
Puma Biotechnology PBYI:US $ 6.66M 0.61M
Regeneron Pharmaceuticals REGN:US $ 2218.5M 227M
Sarepta Therapeutics SRPT:US $ 208.1M 9.1M
Seattle Genetics SGEN:US $ 319.35M 43.61M
Ultragenyx Pharmaceutical RARE:US $ 21.08M 3.27M
United Therapeutics UTHR:US $ 89.9M 1.7M
Vertex Pharmaceuticals VRTX:US $ 367.7M 28.8M
YTE INCY:US $ 54.5M 19.05M